Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions

Phase 1 Completed 28 enrolled Angelini Pharma Cross Research S.A. · collab

RandomizedCrossoverOpen-labelOther

Summary

This study was designed to investigate the bioequivalence of the test and reference products when administered as single oral doses in two consecutive study periods, under fasting conditions.

Timeline

Start: 2020-02-17
Primary completion: 2020-07-19
Completion: 2020-07-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trazodone	Small molecule	300 mg	Oral

Indications

No indication recorded.